APO RESEARCH · REPORT
Radiopharmaceutical
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Product & engineering
Understand the product.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Selected research
Industry Research
Radiopharmaceutical Industry Research Report 2026
Market perspective
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
Report Scope
Read the full market overview
This report quantifies the global Radiopharmaceutical market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radiopharmaceutical Market by Company
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Radiopharmaceutical Segment by Type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Radiopharmaceutical Segment by Application
Oncology
Cardiology
Other
Radiopharmaceutical Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Radiopharmaceutical manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Radiopharmaceutical by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Radiopharmaceutical in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Actinium-225
- Lutetium-177
- Radium-223
- Holmium-166
- Other
Applications
- Oncology
- Cardiology
- Other
Companies covered
- Bracco Imaging
- Bayer
- Mallinckrodt
- Nordion
- Triad Isotopes
- Lantheus
- IBA Group
- GE Healthcare
- China Isotope & Radiation
- Jubilant Pharma
- Eli Lilly
- Advanced Accelerator Applications
- SIEMENS
- Dongcheng
- Navidea
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Radiopharmaceutical Market Size (2021-2032)
- 2.2.2 Global Radiopharmaceutical Sales (2021-2032)
- 2.2.3 Global Radiopharmaceutical Market Average Price (2021-2032)
- 2.3 Radiopharmaceutical by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Actinium-225
- 2.3.3 Lutetium-177
- 2.3.4 Radium-223
- 2.3.5 Holmium-166
- 2.3.6 Other
- 2.4 Radiopharmaceutical by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Oncology
- 2.4.3 Cardiology
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Radiopharmaceutical Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Radiopharmaceutical Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Radiopharmaceutical Revenue of Manufacturers (2021-2026)
- 3.4 Global Radiopharmaceutical Average Price by Manufacturers (2021-2026)
- 3.5 Global Radiopharmaceutical Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Radiopharmaceutical, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Radiopharmaceutical, Product Type & Application
- 3.8 Global Manufacturers of Radiopharmaceutical, Established Date
- 3.9 Global Radiopharmaceutical Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bracco Imaging
- 4.1.1 Bracco Imaging Company Information
- 4.1.2 Bracco Imaging Business Overview
- 4.1.3 Bracco Imaging Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bracco Imaging Radiopharmaceutical Product Portfolio
- 4.1.5 Bracco Imaging Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Radiopharmaceutical Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Mallinckrodt
- 4.3.1 Mallinckrodt Company Information
- 4.3.2 Mallinckrodt Business Overview
- 4.3.3 Mallinckrodt Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mallinckrodt Radiopharmaceutical Product Portfolio
- 4.3.5 Mallinckrodt Recent Developments
- 4.4 Nordion
- 4.4.1 Nordion Company Information
- 4.4.2 Nordion Business Overview
- 4.4.3 Nordion Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Nordion Radiopharmaceutical Product Portfolio
- 4.4.5 Nordion Recent Developments
- 4.5 Triad Isotopes
- 4.5.1 Triad Isotopes Company Information
- 4.5.2 Triad Isotopes Business Overview
- 4.5.3 Triad Isotopes Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Triad Isotopes Radiopharmaceutical Product Portfolio
- 4.5.5 Triad Isotopes Recent Developments
- 4.6 Lantheus
- 4.6.1 Lantheus Company Information
- 4.6.2 Lantheus Business Overview
- 4.6.3 Lantheus Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lantheus Radiopharmaceutical Product Portfolio
- 4.6.5 Lantheus Recent Developments
- 4.7 IBA Group
- 4.7.1 IBA Group Company Information
- 4.7.2 IBA Group Business Overview
- 4.7.3 IBA Group Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 IBA Group Radiopharmaceutical Product Portfolio
- 4.7.5 IBA Group Recent Developments
- 4.8 GE Healthcare
- 4.8.1 GE Healthcare Company Information
- 4.8.2 GE Healthcare Business Overview
- 4.8.3 GE Healthcare Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GE Healthcare Radiopharmaceutical Product Portfolio
- 4.8.5 GE Healthcare Recent Developments
- 4.9 China Isotope & Radiation
- 4.9.1 China Isotope & Radiation Company Information
- 4.9.2 China Isotope & Radiation Business Overview
- 4.9.3 China Isotope & Radiation Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 China Isotope & Radiation Radiopharmaceutical Product Portfolio
- 4.9.5 China Isotope & Radiation Recent Developments
- 4.10 Jubilant Pharma
- 4.10.1 Jubilant Pharma Company Information
- 4.10.2 Jubilant Pharma Business Overview
- 4.10.3 Jubilant Pharma Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Jubilant Pharma Radiopharmaceutical Product Portfolio
- 4.10.5 Jubilant Pharma Recent Developments
- 4.11 Eli Lilly
- 4.11.1 Eli Lilly Company Information
- 4.11.2 Eli Lilly Business Overview
- 4.11.3 Eli Lilly Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Eli Lilly Radiopharmaceutical Product Portfolio
- 4.11.5 Eli Lilly Recent Developments
- 4.12 Advanced Accelerator Applications
- 4.12.1 Advanced Accelerator Applications Company Information
- 4.12.2 Advanced Accelerator Applications Business Overview
- 4.12.3 Advanced Accelerator Applications Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Advanced Accelerator Applications Radiopharmaceutical Product Portfolio
- 4.12.5 Advanced Accelerator Applications Recent Developments
- 4.13 SIEMENS
- 4.13.1 SIEMENS Company Information
- 4.13.2 SIEMENS Business Overview
- 4.13.3 SIEMENS Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 SIEMENS Radiopharmaceutical Product Portfolio
- 4.13.5 SIEMENS Recent Developments
- 4.14 Dongcheng
- 4.14.1 Dongcheng Company Information
- 4.14.2 Dongcheng Business Overview
- 4.14.3 Dongcheng Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Dongcheng Radiopharmaceutical Product Portfolio
- 4.14.5 Dongcheng Recent Developments
- 4.15 Navidea
- 4.15.1 Navidea Company Information
- 4.15.2 Navidea Business Overview
- 4.15.3 Navidea Radiopharmaceutical Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Navidea Radiopharmaceutical Product Portfolio
- 4.15.5 Navidea Recent Developments
5 Global Radiopharmaceutical Market Scenario by Region
- 5.1 Global Radiopharmaceutical Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Radiopharmaceutical Sales by Region: 2021-2032
- 5.2.1 Global Radiopharmaceutical Sales by Region: 2021-2026
- 5.2.2 Global Radiopharmaceutical Sales by Region: 2027-2032
- 5.3 Global Radiopharmaceutical Revenue by Region: 2021-2032
- 5.3.1 Global Radiopharmaceutical Revenue by Region: 2021-2026
- 5.3.2 Global Radiopharmaceutical Revenue by Region: 2027-2032
- 5.4 North America Radiopharmaceutical Market Facts & Figures by Country
- 5.4.1 North America Radiopharmaceutical Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Radiopharmaceutical Sales by Country (2021-2032)
- 5.4.3 North America Radiopharmaceutical Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Radiopharmaceutical Market Facts & Figures by Country
- 5.5.1 Europe Radiopharmaceutical Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Radiopharmaceutical Sales by Country (2021-2032)
- 5.5.3 Europe Radiopharmaceutical Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Radiopharmaceutical Market Facts & Figures by Country
- 5.6.1 Asia Pacific Radiopharmaceutical Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Radiopharmaceutical Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Radiopharmaceutical Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Radiopharmaceutical Market Facts & Figures by Country
- 5.7.1 South America Radiopharmaceutical Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Radiopharmaceutical Sales by Country (2021-2032)
- 5.7.3 South America Radiopharmaceutical Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Radiopharmaceutical Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Radiopharmaceutical Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Radiopharmaceutical Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Radiopharmaceutical Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Radiopharmaceutical Sales by Type (2021-2032)
- 6.1.1 Global Radiopharmaceutical Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Radiopharmaceutical Sales Market Share by Type (2021-2032)
- 6.2 Global Radiopharmaceutical Revenue by Type (2021-2032)
- 6.2.1 Global Radiopharmaceutical Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Radiopharmaceutical Revenue Market Share by Type (2021-2032)
- 6.3 Global Radiopharmaceutical Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Radiopharmaceutical Sales by Application (2021-2032)
- 7.1.1 Global Radiopharmaceutical Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Radiopharmaceutical Sales Market Share by Application (2021-2032)
- 7.2 Global Radiopharmaceutical Revenue by Application (2021-2032)
- 7.2.1 Global Radiopharmaceutical Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Radiopharmaceutical Revenue Market Share by Application (2021-2032)
- 7.3 Global Radiopharmaceutical Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Radiopharmaceutical Value Chain Analysis
- 8.1.1 Radiopharmaceutical Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Radiopharmaceutical Production Mode & Process
- 8.2 Radiopharmaceutical Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Radiopharmaceutical Distributors
- 8.2.3 Radiopharmaceutical Customers
9 Global Radiopharmaceutical Analyzing Market Dynamics
- 9.1 Radiopharmaceutical Industry Trends
- 9.2 Radiopharmaceutical Industry Drivers
- 9.3 Radiopharmaceutical Industry Opportunities and Challenges
- 9.4 Radiopharmaceutical Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst